R&D/Clinical Trials

MIDD can pave new road for drug development.

Mark Davies and Paul Riley outline their blueprint for exploring how healthcare companies can leverage real-world evidence to access and engage customers more effectively.

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.

With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.

How Gilead readied remdesivir for the COVID challenge.

Inside Regeneron’s monoclonal antibody development to treat COVID.

Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.

Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.

College roommates, industry partnerships help bring Pfizer vaccine to fruition.

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.

Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.

Pascal Descargues, Ph.D., founder of Genoskin, talks about how the company is responding to the US government’s push to help pharma and biotech leaders speed clinical drug development and testing.

Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.

The shift to clinical-grade support offers great opportunity.

Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Decentralized tools and technologies will continue to provide new opportunities for patient engagement post-COVID.

R&D on medical treatments lags notable success with vaccines.

Jill Wechsler reports on FDA's newly published strategies supporting broader eligibility criteria for Phase III studies.

Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.

Oral solid dose formulations (OSD) continue to lead the market as a preferred dosage form. To gain better insight into drug dose delivery technology trends, Laura Child spoke to leaders from five top contract development and manufacturing organizations to find out what is on the horizon for patient-centric drug delivery.

Hannah Brown & Elizabeth Baynton explore the atopic dermatitis patient-doctor dynamic and identify opportunities to optimize patient outcomes.

With pharma increasingly exploring the therapeutic potential of psychedelic drugs, Pharm Exec looks at how three companies in this space are developing their pipelines.

Michael Henderson, Chief Business Officer, BridgeBio spoke to Pharm Exec about his efforts in developing potential treatments for rare diseases.

Anthony Finbow, CEO of Eagle Genomics, talks to Pharm Exec about how adding microbiome-based evidence to disease modeling will enable the life sciences industry to understand the subtleties of how drugs interact with different human ‘host’ environments, unlocking new potential for stratified treatments.

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.